SecBot SecBot
6-K ·Filed Aug 12, 2026

BWAY

Brainsway Ltd.
BULLISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001171843-26-005440
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong beat-and-raise quarter with accelerating revenue growth, expanding margins, and record system shipments signals robust demand and operational leverage. Traders should watch the upcoming conference call for details on reimbursement expansion and the minority investment portfolio's contribution. The raised guidance provides a clear catalyst for near-term upside.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.60
T+0 close · Aug 12, 2026 · via day close
Latest settled
−36.08%
T+60 · $10.61
Vs SPY
−30.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $16.60entry
  2. T+1 · 3mo ago −0.78%α −1.48% · $16.47
  3. T+5 · 3mo ago −8.61%α −8.17% · $15.17
  4. T+20 · 2mo ago −16.20%α −14.31% · $13.91
  5. T+60 · 12d ago −36.08%α −30.97% · $10.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay reported a record Q2 2026 with revenue up 35% YoY to $17.1M, net income up 34% to $2.7M, and Adjusted EBITDA more than doubling to $3.5M with margin expanding to 20%. The company raised full-year 2026 revenue guidance to $68M-$70M and EBITDA guidance to $13M-$14M, driven by record system shipments (125 units, +42% YoY) and growing RPO of $80.4M. This strong operational momentum, supported by expanding reimbursement coverage and a healthy balance sheet ($62.4M cash), reinforces the bullish trajectory from the prior 20-F annual report.

Key Facts

  • Q2 2026 revenue increased 35% YoY to $17.1M, a record.
  • Net income rose 34% YoY to $2.7M; diluted EPS was $0.07 vs $0.05.
  • Adjusted EBITDA more than doubled to $3.5M, with margin expanding to 20% from 11%.
  • Shipped a record 125 Deep TMS systems in Q2, up 42% YoY; installed base ~1,949.
  • Remaining performance obligations (RPO) grew 30% YoY to $80.4M.
  • Raised FY 2026 revenue guidance to $68M-$70M (from $66M-$68M) and Adjusted EBITDA guidance to $13M-$14M (from $12M-$14M).
  • Cash and cash equivalents totaled $62.4M as of June 30, 2026, up ~6% from March 31, 2026.
  • Generated $6.3M of cash flow from operations in Q2 2026.

Financial Impact

Revenue growth of 35% YoY to $17.1M; net income growth of 34% to $2.7M; Adjusted EBITDA growth of 141% to $3.5M; raised FY 2026 revenue guidance by $2M at midpoint to $69M.

revenuenet incomeadjusted EBITDAoperating cash flowsystem shipmentsRPO

Risk Factors

  • Patent litigation with Magnus Medical remains an overhang, though no update was provided in this filing.
  • Reliance on a single large customer (noted in prior 20-F) and execution risk on the minority investment portfolio could temper growth.
  • Forward guidance assumes continued reimbursement expansion and installed base utilization, which may face competitive or regulatory headwinds.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005440
Document: f6k_081126.htm0001171843-26-005440
Document: 0001171843-26-005440-index-headers.html0001171843-26-005440
Document: 0001171843-26-005440-index.html0001171843-26-005440
Document: 0001171843-26-005440.txt0001171843-26-005440

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026